Improvement of Irritable Bowel Syndrome with Glucagon like peptide-1 Receptor Agonists: A Systematic Review and Meta-analysis

Mostafa, Mohamed E A; Alrasheed, Tariq

doi:10.3389/fendo.2025.1548346

SYSTEMATIC REVIEW article

Front. Endocrinol.

Sec. Gut Endocrinology

Volume 16 - 2025 | doi: 10.3389/fendo.2025.1548346

Improvement of Irritable Bowel Syndrome with Glucagon like peptide-1 Receptor Agonists: A Systematic Review and Meta-analysis

Provisionally accepted

Mohamed E A Mostafa ^*

Tariq Alrasheed

University of Tabuk, Tabuk, Saudi Arabia

The final, formatted version of the article will be published soon.

AbstractIntroduction: Irritable bowel syndrome (IBS) is a severe gastrointestinal condition with symptoms like pain, bloating, diarrhea, and constipation. Glucagon-like peptide-1 (GLP-1) receptors, expressed in the central nervous system and peripheral tissues, have been found to affect gut motility. GLP-1 and its analog ROSE-010 have been shown to inhibit the migrating motor complex and decrease gastrointestinal motility in IBS patients.Aim: This systematic review and meta-analysis aim to assess the efficacy and safety of GLP-1 receptor agonists in providing pain and symptom relief for individuals with IBS.Methods: The study conducted extensive searches across various databases, including Cochrane Library, Web of Science, PubMed, Google Scholar, and Science Direct, to identify studies on IBS and related drugs. A search strategy using keywords and medical subject heading terms (MeSH) was developed to ensure inclusivity. Exclusion criteria included non-English language studies, books, conference papers, case reports, in vitro studies, animal studies, and non-original articles.Results: The study found that ROSE-010 (100 µg) significantly lowered pain intensity in IBS patients compared to a placebo, with an overall odds ratio of 2.30, 95% CI: 1.53-3.46. ROSE-010 (300 µg) is more effective than a placebo for all irritable bowel syndrome subtypes, with consistent effects across trials. ROSE-010 is linked to a greater incidence of nausea, vomiting, and headache than placebo.Conclusion: ROSE-010, a glucagon-like peptide-1 receptor agonist, has been shown to reduce pain in individuals with IBS. However, its higher frequency of nausea, vomiting, and headache suggests the need for close monitoring and individualized treatment plans. Further investigation is needed to understand its impact on different IBS subtypes and long-term effects.

Keywords: Glucagon like peptid 1, irritable bowel síndrome, Pain, IBS, Agonis

Received: 19 Dec 2024; Accepted: 10 Feb 2025.

Copyright: © 2025 Mostafa and Alrasheed. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Mohamed E A Mostafa, University of Tabuk, Tabuk, Saudi Arabia

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.